Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02606136
Recruitment Status : Active, not recruiting
First Posted : November 17, 2015
Results First Posted : December 30, 2021
Last Update Posted : December 30, 2021
Sponsor:
Information provided by (Responsible Party):
FibroGen

Brief Summary:
This is a Phase 2, open-label, single arm trial of pamrevlumab (FG-3019) to estimate pamrevlumab's safety and efficacy in non-ambulatory participants with DMD.

Condition or disease Intervention/treatment Phase
Duchenne Muscular Dystrophy Drug: Pamrevlumab Phase 2

Detailed Description:
The study will include a screening period, main study period, open-label extension (OLE) period, and follow-up period 4 weeks after the last dose. All participants who complete the main portion of the study for a minimum of 104 weeks (2 years) will be rolled over to an OLE for up to an additional 208 weeks (4 years).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Actual Study Start Date : January 4, 2016
Actual Primary Completion Date : May 7, 2020
Estimated Study Completion Date : January 31, 2023


Arm Intervention/treatment
Experimental: Pamrevlumab
Participants will receive pamrevlumab 35 milligrams (mg)/kilogram (kg) by intravenous (IV) infusion every 2 weeks for a minimum of 104 weeks.
Drug: Pamrevlumab
Pamrevlumab, 10 milligrams (mg)/milliliter (mL), single dose vials
Other Name: Monoclonal Antibody to Connective tissue growth factor (CTGF), FG-3019




Primary Outcome Measures :
  1. Annual Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) at Week 104 [ Time Frame: Baseline, Week 104 ]
    FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC was the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity. Percent of predicted FVC = (observed value)/(predicted value) * 100%. Analysis was done using a random coefficient model (RCM), which included visit in years (as a continuous variable), and baseline efficacy as fixed effects, the intercept and the linear slope of visit as random effect, and individual participants as participant effect.


Secondary Outcome Measures :
  1. Change From Baseline in Percent Predicted Forced Expiratory Volume at 1 Second (ppFEV1) at Week 104 [ Time Frame: Baseline, Week 104 ]
    FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Predicted FEV1 is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity. Percent of predicted FEV1= (observed value)/(predicted value) * 100%. Analysis was done using an RCM, which included visit in years (as a continuous variable), and baseline efficacy as fixed effects, the intercept and the linear slope of visit as random effect, and individual participants as participant effect.

  2. Change From Baseline in Percent Predicted Peak Expiratory Flow (PEF) at Week 104 [ Time Frame: Baseline, Week 104 ]
    Percent predicted PEF is a measure of the maximal or peak flow produced during an exhalation with maximal effort and, as such, is the most effort-dependent measure of lung function. Analysis was done using an RCM, which included visit in years (as a continuous variable), and baseline efficacy as fixed effects, the intercept and the linear slope of visit as random effect, and individual participants as participant effect.

  3. Change From Baseline in Left Ventricular Ejection Fraction Percentage (LVEF%) at Week 104 [ Time Frame: Baseline, Week 104 ]
    LVEF% is an important measure of cardiac function. LVEF is a fraction of blood (in percent) pumped out of the left ventricle of the heart (the main pumping chamber). Analysis was done using an RCM, which included visit in years (as a continuous variable), and baseline efficacy as fixed effects, the intercept and the linear slope of visit as random effect, and individual participants as participant effect.

  4. Change From Baseline in Performance of Upper Limb (PUL) Total Score at Week 104 [ Time Frame: Baseline, Week 104 ]
    The PUL was used to assess motor performance of the upper limb. The PUL scale includes 22 items; an entry item defining the starting functional level, and 21 items subdivided into shoulder level (4 items), elbow level (9 items), and distal level (8 items) dimensions. Scoring options per item may not be uniform and may vary from 0-1 and 0-6, according to the performance, with higher values corresponding to better performance. Each dimension was scored separately with a maximum score of 16 for shoulder level, 34 for elbow level, and 24 for distal level. Total score was calculated by adding the 3 level scores, with a maximum global score of 74 (total score range = 0-74). Higher score = better outcome. Analysis was done using an RCM, which included visit in years (as a continuous variable), and baseline efficacy as fixed effects, the intercept and the linear slope of visit as random effect, and individual participants as participant effect.

  5. Change From Baseline in Grip Strength by Hand, as Measured by Hand Held Myometry (HHM) at Week 104 [ Time Frame: Baseline, Week 104 ]
    The HHM was used to measure distal upper arm strength (grip strength). Data has been presented by dominant and non-dominant hand. Analysis was done using an RCM, which included visit in years (as a continuous variable), and baseline efficacy as fixed effects, the intercept and the linear slope of visit as random effect, and individual participants as participant effect.

  6. Change From Baseline in Pinch Strength, as Measured by HHM at Week 104 [ Time Frame: Baseline, Week 104 ]
    The HHM was used to measure distal upper arm strength (pinch strength). Data has been presented by dominant and non-dominant hand. Analysis was done using an RCM, which included visit in years (as a continuous variable), and baseline efficacy as fixed effects, the intercept and the linear slope of visit as random effect, and individual participants as participant effect.

  7. Change From Baseline in Cardiac Fibrosis (Scar Mass), as Measured by Magnetic Resonance Imaging (MRI) at Week 104 [ Time Frame: Baseline, Week 104 ]
    Cardiac MRI was used to assess the cardiac fibrosis by detecting the presence of late gadolinium enhancement (LGE), a marker for myocardial fibrosis. Analysis was done using an RCM, which included visit in years (as a continuous variable), and baseline efficacy as fixed effects, the intercept and the linear slope of visit as random effect, and individual participants as participant effect.

  8. Change From Baseline in Upper Arm (Biceps Brachii MRI) Muscle Fat and Fibrosis Score, as Measured by MRI at Week 104 [ Time Frame: Baseline, Week 104 ]
    T2-mapping with MRI was conducted to measure upper arm muscle fibrosis and fat in the biceps brachii muscle. Analysis was done using an RCM, which included visit in years (as a continuous variable), and baseline efficacy as fixed effects, the intercept and the linear slope of visit as random effect, and individual participants as participant effect. The visual score for muscle fat and fibrosis will be assessed using a modified 5-point Mercuri score in which 0 = normal muscle appearance and 5 = complete replacement of muscle by connective tissue and fat, where a lower score indicated visually healthier muscle. Change from baseline was calculated as the score at Week 104 - the score at baseline.

  9. Change From Baseline in Fat Fraction Percentage (%F), as Measured by MRI at Week 104 [ Time Frame: Baseline, Week 104 ]
    Analysis was done using an RCM, which included visit in years (as a continuous variable), and baseline efficacy as fixed effects, the intercept and the linear slope of visit as random effect, and individual participants as participant effect.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written consent/assent by participant and/or legal guardian as per regional and/or institutional review board (IRB) requirements
  • Non-ambulatory
  • Brooke Score for Arms and Shoulders ≤5
  • Diagnosis of DMD by medical history and confirmed Duchenne mutation in available genetic testing using a validated genetic test
  • Able to perform spirometry
  • Able to undergo cardiac and extremity (upper arm) MRI
  • Percent predicted FVC between 40 and 90, inclusive
  • At least one historical ppFVC predicted value within 18 months of baseline
  • Left ventricular ejection fraction ≥ 45% as determined by cardiac MRI at screening or within 3 months prior to Day 0
  • Participants currently receiving heart failure cardiac medications (for example, angiotensin converting enzyme inhibitors, angiotensin-receptor blockers, and beta-blockers) must achieve a stable regimen for at least 3 months prior to screening
  • On a stable dose of corticosteroids for a minimum of 6 months prior to screening with no substantial change in dosage for a minimum of 3 months (except for adjustments for changes in body weight) prior to screening and no foreseen change in corticosteroid use during the course of study participation
  • Received pneumococcal vaccine and is receiving annual influenza vaccinations
  • Adequate renal function: cystatin C ≤1.4 mg/liter (L)
  • Adequate hematological function

    1. Platelets >100,000/microliter (μL)
    2. Hemoglobin >12 grams (g)/deciliter (dL)
    3. Absolute neutrophil count >1500/μL
  • Adequate hepatic function

    1. No history or evidence of liver disease
    2. Gamma glutamyl transferase (GGT) ≤3 x upper limit of normal (ULN)
    3. Total bilirubin ≤1.5 x ULN
  • If sexually active, will use medically accepted contraceptives during participation in the study and for 3 months after the last dose of study drug

Exclusion Criteria:

  • Requires ≥16 hours continuous ventilation
  • Prior or ongoing medical condition that, in the investigator's opinion, could adversely affect the safety of the participant, makes it unlikely that the course of 156 weeks of treatment and follow-up would be completed, or could impair the assessment of study results
  • Anticipated spine surgery within 156 weeks
  • Severe uncontrolled heart disease, including any of the following:

    1. Need for intravenous diuretics or inotropic support within 3 months prior to screening
    2. Hospitalization for a heart failure exacerbation or arrhythmia in last 3 months
  • Arrhythmia requiring anti-arrhythmic therapy
  • Hospitalization due to respiratory failure in the last 6 weeks
  • Poorly controlled asthma or underlying lung disease such as bronchopulmonary dysplasia
  • Known or suspected active hepatitis B or C or history of human immunodeficiency virus (HIV)
  • Body mass index (BMI) ≥40 kilograms (kg)/square meter (m^2) or weight >117 kg
  • Exposure to another investigational drug or another approved product for DMD (for example, eteplirsen or golodirsen) within 28 days prior to start of study treatment
  • Exposure to another investigational drug or another approved product for DMD (e.g. eteplirsen) within 28 days prior to start of study treatment (or 5 half-lives of the product whichever is longer) prior to first screening visit with the exception of deflazacort. Use of deflazacort, if regarded by the principal investigator as standard of care, is allowed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02606136


Locations
Layout table for location information
United States, California
David Geffen School of Medicine at UCLA
Los Angeles, California, United States, 90095
University of California San Francisco - Benioff Children's Hospital
San Francisco, California, United States, 94143
United States, Colorado
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
United States, Georgia
Rare Disease Research
Atlanta, Georgia, United States, 30318
United States, Massachusetts
Boston Children's Hospital
Boston, Massachusetts, United States, 02115
United States, Missouri
Washington University in St. Louis School of Medicine
Saint Louis, Missouri, United States, 63110
United States, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
United States, Oregon
Shriner's Hospital for Children - Portland
Portland, Oregon, United States, 97239
United States, Pennsylvania
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
Children's Medical Center Ambulatory Care Pavilion
Dallas, Texas, United States, 75207
Sponsors and Collaborators
FibroGen
  Study Documents (Full-Text)

Documents provided by FibroGen:
Study Protocol  [PDF] September 27, 2019
Statistical Analysis Plan  [PDF] June 25, 2020

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: FibroGen
ClinicalTrials.gov Identifier: NCT02606136    
Other Study ID Numbers: FGCL-3019-079
First Posted: November 17, 2015    Key Record Dates
Results First Posted: December 30, 2021
Last Update Posted: December 30, 2021
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Keywords provided by FibroGen:
Duchenne
muscular
dystrophy
DMD
non-ambulatory
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Mitogens
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action